Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00594542 |
| Other study ID # |
UPenn IRB-806101 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
June 2007 |
| Est. completion date |
September 2007 |
Study information
| Verified date |
November 2023 |
| Source |
University of Pennsylvania |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The purpose of the study will be to demonstrate whether Mohs micrographic surgery can be
performed with a lower total dose of local anesthesia (and greater patient safety) when using
0.5% lidocaine with 1:200,000 epinephrine versus 1% lidocaine with 1:100,000 epinephrine.
Description:
The purpose of the study will be to demonstrate whether Mohs micrographic surgery can be
performed with a lower total dose of local anesthesia (and greater patient safety) when using
0.5% lidocaine with 1:200,000 epinephrine versus 1% lidocaine with 1:100,000 epinephrine.
Mohs micrographic surgery is a multi-staged, same-day procedure used to remove skin cancers
under local anesthesia. Reconstruction of the surgical wound is also performed under local
anesthesia, usually immediately after achieving tumor clearance.
This randomized, double-blind study will systematically compare the total dose of 1.0%
lidocaine with 1:100,000 epinephrine versus 0.5% of lidocaine with 1:200,000 epinephrine
needed to achieve local anesthesia during Mohs micrographic surgery (MMS). All healthy adult
volunteers (18 years or older) undergoing Mohs micrographic surgery at the Hospital of the
University of Pennsylvania's Department of Dermatology and Dermatologic Surgery between June
1, 2007 and August 31, 2007 will be eligible to participate in the study. Our primary
intervention will be to record the total dose of lidocaine administered throughout all of the
MMS stages and reconstructions using either of the two lidocaine concentrations. A secondary
intervention will be to record each patient's level of pain control in order to demonstrate
that patient comfort is effectively achieved with a lower total dose of local anesthesia.
Pregnant or breast-feeding subjects, those with a history of allergic or other adverse
reaction to lidocaine or epinephrine, and those who are cognitively impaired will be
excluded. In addition, if the surgeon believes that a patient has a tumor which, due to size
or anatomic site, may put him at risk for requiring a dose of lidocaine that approaches the
threshold of toxicity, this patient will be excluded from the study.